Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology Virtual
31 mars 2020 08h00 HE
|
Resverlogix Corp
BETonMACE shows apabetalone treatment was associated with 41% reduction in hospitalizations for heart failure in patients with type 2 diabetes and recent Acute Coronary Syndrome Preclinical findings...
Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association
30 mars 2020 08h00 HE
|
Resverlogix Corp
Announces publication of accompanying JAMA editorial highlighting important secondary endpoints including congestive heart failure Apabetalone development program moving toward next study to enable a...
近期出版物对Resverlogix临床候选药物Apabetalone作为新冠肺炎（COVID-19）潜在治疗药物进行专题报道
24 mars 2020 12h05 HE
|
Resverlogix Corp
阿尔伯塔省卡尔加里, March 25, 2020 (GLOBE NEWSWIRE) -- Resverlogix...
Resverlogix 臨床候選產品 Apabetalone 在近期刊物中被視為潛在的 COVID-19 治療藥物
24 mars 2020 12h05 HE
|
Resverlogix Corp
阿爾伯塔省卡爾加里, March 25, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (「Resverlogix」或「公司」) (TSX:RVX)，欣然宣佈 2020 年 3 月 23 日的 bioRxiv 刊物顯示 apabetalone 可抑制專業化蛋白質，或稱為溴結構域和末端外蛋白 (bromodomain and extraterminal...
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
24 mars 2020 08h00 HE
|
Resverlogix Corp
CALGARY, Alberta, March 24, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce a March 23, 2020 bioRxiv publication that has shown...
Resverlogix为Apabetalone用于对抗新冠肺炎传播的新试验和新研究诚邀合作方
23 mars 2020 12h29 HE
|
Resverlogix Corp
阿尔伯塔省卡尔加里, March 24, 2020 (GLOBE NEWSWIRE) -- Resverlogix...
邀請 Resverlogix 合作，在試驗和研究中使用 Apabetalone，以對抗新冠狀病毒的傳播
23 mars 2020 12h29 HE
|
Resverlogix Corp
阿爾伯塔省卡加利, March 24, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp.（以下簡稱「 Resverlogix」）（TSX：RVX）宣佈正為臨床前或臨床模型，尋求與目前正在測試...
Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research
23 mars 2020 07h00 HE
|
Resverlogix Corp
CALGARY, Alberta, March 23, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”) (TSX: RVX) announces that it is seeking to collaborate with organizations currently testing therapies for...
Resverlogix Receives US FDA Breakthrough Therapy Designation for Apabetalone
03 févr. 2020 07h30 HE
|
Resverlogix Corp
CALGARY, Alberta, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) is pleased to announce the U.S. Food & Drug Administration (“FDA”) has granted...
CORRECTION: Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
13 janv. 2020 09h17 HE
|
Resverlogix Corp
CALGARY, Alberta, Jan. 13, 2020 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Resverlogix Corp. (TSX: RVX), please note that the subheadline should read "BETonMACE...